Evidence map›Paper›PMID 22955798›Full record

ArticleRheumatology international2013

EBV reactivation serological profile in primary Sjögren's syndrome: an underlying trigger of active articular involvement?

Sandra Gofinet Pasoto, Renato Romera Natalino, Henrique Pires Chakkour, Vilma Dos Santos Trindade Viana, Cleonice Bueno, Elaine Pires Leon, Margarete Borges Gualhardo Vendramini, Mauricio Levy Neto, Eloisa Bonfa

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. EBV Genome Variations and Association With Diseases.Journal of medical virology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Infections as Risk Factor of Sjögren's Syndrome.Open access rheumatology : research and reviews · 2020
    Review
  13. New Viral Facets in Oral Diseases: The EBV Paradox.International journal of molecular sciences · 2019
    Review
  14. Observational
  15. Sjögren's syndrome and systemic lupus erythematosus: links and risks.Open access rheumatology : research and reviews · 2019
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Autoimmunity and the gut.Autoimmune diseases · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sandra Gofinet PasotoRheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (USP), São Paulo, Brazil. sandrapasoto@yahoo.com.br
Renato Romera Natalino
Henrique Pires Chakkour
Vilma Dos Santos Trindade Viana
Cleonice Bueno
Elaine Pires Leon
Margarete Borges Gualhardo Vendramini
Mauricio Levy Neto
Eloisa Bonfa
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody to Epstein-Barr virus (EBV) early antigen diffuse (anti-EA-D) is associated with viral replication. However, their possible associations with clinical/therapeutic features in primary Sjögren's syndrome (pSS) were not established. We evaluated 100 pSS patients (American-European Criteria) and 89 age/gender/ethnicity-matched healthy controls. Disease activity was measured by EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). Antibodies to EBV (anti-VCA IgG/IgM, anti-EBNA-1 IgG, anti-EA-D IgG) were determined by ELISA. Patients and controls had comparable frequencies and mean levels of anti-VCA IgG (90 vs. 86.5 %, p = 0.501; 2.6 ± 1.1 vs. 2.5 ± 1.1 AU/mL, p = 0.737) and anti-EBNA-1 IgG (92 vs. 94.4 %, p = 0.576; 141.3 ± 69.8 vs. 135.6 ± 67.5 RU/mL, p = 0.464). Anti-VCA IgM was negative in all cases. Noteworthy, higher frequency and increased mean levels of anti-EA-D were observed in patients than controls (36 vs. 4.5 %, p < 0.0001; 38.6 ± 57.4 vs. 7.9 ± 26.3 RU/mL, p < 0.0001). Further analysis of patients with (n = 36) and without (n = 64) anti-EA-D revealed comparable age/gender/ethnicity (p ≥ 0.551), current prednisone dose (4.8 ± 6.9 vs. 5.1 ± 10.4 mg/day, p = 0.319), and current uses of prednisone (52.8 vs. 37.5 %, p = 0.148) and immunosuppressants (44.4 vs. 31.3 %, p = 0.201). ESSDAI values were comparable (p = 0.102), but joint activity was more frequent (25 vs. 9.4 %, p = 0.045) in anti-EA-D positive patients. Anti-EA-D antibodies were not associated with anti-Ro/SSA (p = 1.000), anti-La/SSB (p = 0.652), rheumatoid factor (p = 1.000), anti-α-fodrin (p = 0.390) or antiphospholipid antibodies (p = 0.573), not suggesting cross-reactivity. The higher anti-EA-D frequency associated with joint activity raises the possibility that a subclinical EBV reactivation may trigger or perpetuate the articular involvement in pSS.

Indexed as

Virus ActivationAdultAntibodies, AntinuclearAntibodies, ViralAntigens, ViralBiomarkersCase-Control StudiesChi-Square DistributionDisease ProgressionEnzyme-Linked Immunosorbent AssayFemaleGlucocorticoidsHerpesvirus 4, HumanHumansImmunoglobulin GImmunoglobulin MAntibodies, AntinuclearAntibodies, ViralAntigens, ViralBiomarkersEpstein-Barr virus early antigen diffuse componentGlucocorticoidsImmunoglobulin GImmunoglobulin MImmunosuppressive AgentsPrednisone

Identifiers

PMID22955798
OpenAlexW1998244390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.